{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zolinza+%28vorinostat%29", "query": { "intervention": "Zolinza (vorinostat)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 204, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zolinza+%28vorinostat%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T21:28:16.591Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00243100", "title": "Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2005-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-16", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243100" }, { "nct_id": "NCT00005634", "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005634" }, { "nct_id": "NCT02589145", "title": "Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Caphosol", "type": "DRUG" }, { "name": "Glutamine", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2016-06-22", "completion_date": "2019-04-08", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589145" }, { "nct_id": "NCT03426891", "title": "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Brain Tumor", "GBM" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-16", "completion_date": "2023-06-28", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03426891" }, { "nct_id": "NCT00764517", "title": "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Indolent Adult Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2008-08", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 2, "location_summary": "Portland, Oregon • Hershey, Pennsylvania", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00764517" }, { "nct_id": "NCT01276717", "title": "Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Drug: Carfilzomib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 2, "location_summary": "Rochester, New York • Richmond, Virginia", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276717" }, { "nct_id": "NCT01249443", "title": "Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection", "Recurrent Anal Cancer", "Recurrent Breast Cancer", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage IV Anal Cancer", "Stage IV Breast Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2013-11", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01249443" }, { "nct_id": "NCT00838929", "title": "Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-03", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00838929" }, { "nct_id": "NCT01378481", "title": "High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2012-06", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01378481" }, { "nct_id": "NCT01193842", "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AIDS-Related Plasmablastic Lymphoma", "AIDS-Related Primary Effusion Lymphoma", "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage I Grade 3 Follicular Lymphoma", "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "HIV Infection", "Plasmablastic Lymphoma", "Primary Effusion Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2010-10-06", "completion_date": "2022-05-19", "has_results": true, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-10-01T21:28:16.591Z", "location_count": 35, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193842" } ] }